Physician profile
Tarun Mullick
NPI 1912906462
$60,606.96
in general payments reported to CMS, 2019-2025
17 companies · $145 in 2025
The $145 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41K · 2020: $6,771 · 2021: $7,289 · 2022: $2,259 · 2023: $3,074 · 2024: $22.69 · 2025: $145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,000 · Food and Beverage: $242.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,000.00 |
| Food and Beverage | $241.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $41,610.76 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $17,337.93 | 2020-2023 | |
| Abbvie INC. | $395.53 | 2019-2022 | |
| Gilead Sciences, INC. | $291.83 | 2019-2021 | |
| Ucb, INC. | $163.19 | 2019-2020 | |
| Pfizer INC. | $150.55 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $145.04 | 2025 | Terlivaz |
| Janssen Biotech, INC. | $121.69 | 2019-2023 | Stelara |
| Intercept Pharmaceuticals, INC. | $89.28 | 2019-2021 | |
| Ferring Pharmaceuticals INC. | $82.32 | 2021 | |
| Boston Scientific Corporation | $49.58 | 2023-2024 | Watchman Flx |
| Alfasigma USA, INC. | $44.83 | 2020 | |
| Alexion Pharmaceuticals, INC. | $39.36 | 2022-2023 | Ultomiris |
| Braintree Laboratories, INC. | $38.40 | 2022 | |
| Qol Medical, LLC | $20.33 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $14.13 | 2021 | |
| Redhill Biopharma INC. | $12.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tarun Mullick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.